Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Phase I/II Clinical Trial of Recombinant Novel Coronavirus (COVID-19) Vaccine (Adenovirus Type 5 Vector) for Inhalation

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04840992
Recruitment Status : Recruiting
First Posted : April 12, 2021
Last Update Posted : August 2, 2021
Sponsor:
Collaborators:
Beijing Institute of Biotechnology
Jiangsu Province Centers for Disease Control and Prevention
Information provided by (Responsible Party):
CanSino Biologics Inc.

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : April 15, 2022
Estimated Study Completion Date : July 15, 2022